On October 5, GRAIL, Inc. rose 5.13% in Regular Trading, trading at $150.25 per share with turnover of $51.9972 million.

The stock movement appears driven by UBS Securities raising its price target for the company to $175 from $105 while reiterating its buy rating, signifying reinforced bullish sentiment.

UBS underscored an improved risk-reward outlook following supportive FDA developments affecting GRAIL's Galleri multi-cancer detection test, which has demonstrated efficacy in clinical trials and remains under regulatory review for potential FDA approval.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)